July 20, 2016
Single-agent Adcetris (brentuximab vedotin) has shown a complete remission in 33% of relapsed or refractory classical Hodgkin lymphoma patients, of whom 38% remained in remission for over five years, according to the final data from a pivotal PII study. The...read more